Skip to main content

American medical device specialist joins the board of directors of WATGEN MEDICAL A/S

Written by Customer Service on . Posted in Public Companies.

Company Announcement No. 20
Vejle, December 6th, 2019
 Waturu Holding A/S owns 87.5% of WATGEN MEDICAL A/S. The remaining ownership is split between Belair Medical ApS with 10%, owned by co-founder, doctor and professor, Peter Bjerring and by Huidzaken Holding ApS with 2.5%, owned by Jesper Nørregaard, CEO WATGEN MEDICAL A/S.WATGEN MEDICAL A/S is developing solutions to ensure better treatment of chronic wound care patients. WATGEN MEDICAL A/S also researches in the development of a new type of treatment for patients with inflammatory skin diseases such as childhood eczema.
About the new board profile:More information:
CEO Toke Reedtz, tel .: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, tel .: +45 2720 6214, e-mail: mn@waturu.comNasdaq First North Growth Market Important links:The website:
www.waturu.com
Financial reports:
www.waturu.com/documentsContinuous updates from the company:
www.waturu.com/news
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.